JW (Cayman) Therapeutics (2126.HK) Earnings Analysis
JW (Cayman) Therapeutics (2126.HK) next reports earnings on 2026-09-01. Last quarter (2024-08-28) it beat with EPS -0.62463 HKD vs -0.68764 HKD est (+9.2%). It has beaten estimates in 1/1 recent quarters (100%). Trailing P/E -1.07.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 2126.HK next report earnings?
| Next earnings date | 2026-09-01 |
|---|---|
| Consensus EPS estimate | n/a |
| Revenue estimate | n/a |
2126.HK earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2024-08-28 | -0.62463 HKD | -0.68764 HKD | +9.2% | Beat |
Beat rate: 1/1 (100%) over reported quarters with consensus data.
2126.HK valuation and analyst view
| Trailing P/E | -1.07 |
|---|---|
| Trailing EPS | -1.32349 HKD |
| Price / book | 1.06 |
| Dividend yield | 0.00% |
| Market cap | 0.70B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is JW (Cayman) Therapeutics (2126.HK)'s next earnings date?
JW (Cayman) Therapeutics is next scheduled to report on 2026-09-01.
Did 2126.HK beat earnings last quarter?
In its 2024-08-28 report, 2126.HK posted EPS of -0.62463 HKD versus a -0.68764 HKD estimate — a beat of 9.2%.
What is 2126.HK's earnings track record?
Over the last 1 reported quarters with consensus data, 2126.HK beat estimates 1 times (100%).
What is 2126.HK's current P/E ratio and EPS?
2126.HK trades at a trailing P/E of -1.07 on trailing EPS of -1.3234888925219264 HKD.
What do analysts rate 2126.HK?
2126.HK has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.